Mumbai, July 22 (IANS) Dr Reddy’s Laboratories on Wednesday reported a 69 per cent year-on-year (YoY) decline in its consolidated net profit for the first quarter of FY27, with earnings taking a hit from lower revenues in its global generics business, declining North America sales and disruptions in semaglutide supplies.According to the company’s regulatory filing with the National Stock Exchange (NSE), net profit attributable to the owners of the company stood at Rs 4,435 crore during the April…
Latest Semaglutide News & Updates
Mumbai, July 9 (IANS) Torrent Pharmaceuticals on Thursday announced a voluntary recall of select batches of its Semalix injection disposable pens as a precautionary measure after manufacturing partner Dr Reddy’s Laboratories identified a quality issue requiring technical evaluation.The recall is limited to select batches of Semalix Injection 2 mg and 4 mg manufactured by Dr Reddy’s Laboratories.Torrent clarified that the action is being taken purely as a precaution and said there is no risk to p…
New Delhi, April 4 (IANS) India’s drug regulators are stepping up oversight of fast-growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.The move comes as the Indian Pharmacopoeia Commission (IPC), which functions under the Ministry of Health, has been tasked with systematically collecting and analysing adverse event reports linked to these drugs.The initiative aims to…
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.The companies, namely Sun Pharma, Zydus Lifesciences, and Dr. Reddy’s Laboratories, launched their variants a day after Hyderabad-based Natco Pharma launched its generic semaglutide injection in India, priced at Rs 1,290 per month.Sun Pharma launched semaglutide…